Bosnia and Herzegovina vs Malta: Share of S. aureus infections resistant to methicillin
Bosnia and Herzegovina
26.5%
in 2022
Malta
19.9%
in 2022
Bosnia and Herzegovina rank
23rd
Malta rank
24th
Share of S. aureus infections resistant to methicillin over time
- Bosnia and Herzegovina
- Malta
How they compare
Bosnia and Herzegovina currently reports 26.5% against 19.9% in Malta, a difference of 6.6%.
That makes Bosnia and Herzegovina's figure about 1.3 times Malta's.
The two have swapped places 1 time across 6 shared years of data; in 2017 it was Malta ahead.
Bosnia and Herzegovina ranks 23rd and Malta ranks 24th of 45 countries.
Across the 2 decades both report, Bosnia and Herzegovina averaged higher in 1 and Malta in 1.
Head to head by decade
| Decade | Bosnia and Herzegovina | Malta | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 17.6% | 33.9% | 16.4% | Malta |
| 2020s | 23.5% | 19.9% | 3.6% | Bosnia and Herzegovina |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of s. aureus infections resistant to methicillin, Bosnia and Herzegovina or Malta?
- Bosnia and Herzegovina, at 26.5% against 19.9% in Malta as of 2022.
- What is the difference in share of s. aureus infections resistant to methicillin between Bosnia and Herzegovina and Malta?
- 6.6%, with Bosnia and Herzegovina ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Malta?
- 6 years are reported by both, from 2017 to 2022.
- How do Bosnia and Herzegovina and Malta rank globally for share of s. aureus infections resistant to methicillin?
- Bosnia and Herzegovina ranks 23rd and Malta ranks 24th of 45 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of S. aureus infections resistant to methicillin. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%).